We know that statins have the ability to reduce total cholesterol and some studies have shown that the reduction of cholesterol combined with their positive effect on CRP may reduce the number of cardiac events: http://www.webmd.com/heart-disease/news/20081110/crestor-faq-new-benefits-for-statins?page=2
Nevertheless other studies show that there is no significant effect of statins on total mortality (deaths) http://archinte.ama-assn.org/cgi/content/short/170/12/1024
http://www.spacedoc.net/crestor_omega3_heart_failure
my question is whether those that design the studies for new drugs are (or should be) required under scientific norms, to look for total mortality rather than ONLY mortality from a specific cause, because in the latter case they may well hide the negative effect of a drug on other parts or functions of the body, such as the liver function for statins. Although I am using statins as the example I know, of course my question is general, about the drug testing procedures that are (or should be) used.
